Brokerages expect Bristol-Myers Squibb (NYSE:BMY) to report earnings of $1.93 per share

0

Wall Street analysts expect Bristol-Myers Squibb (NYSE:BMY – Get Rating) to post earnings of $1.93 per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Bristol-Myers Squibb earnings, with the highest EPS estimate of $2.05 and the lowest estimate of $1.83. Bristol-Myers Squibb reported earnings per share of $1.74 in the same quarter last year, which would indicate a positive year-over-year growth rate of 10.9%. The company is expected to announce its next quarterly results before the market opens on Friday, April 29.

On average, analysts expect Bristol-Myers Squibb to report annual earnings of $7.79 per share for the current fiscal year, with EPS estimates ranging from $7.68 to $7.90. For the next fiscal year, analysts expect the company to report earnings of $8.21 per share, with EPS estimates ranging from $7.65 to $8.46. Zacks Investment Research’s EPS averages are an average based on a survey of research companies that cover Bristol-Myers Squibb.

Bristol-Myers Squibb (NYSE:BMY – Get Rating) last announced its quarterly results on Thursday, February 3. The biopharmaceutical company reported earnings per share (EPS) of $1.83 for the quarter, beating analyst consensus estimates of $1.80 by $0.03. Bristol-Myers Squibb had a net margin of 15.08% and a return on equity of 45.60%. The company posted revenue of $11.96 billion for the quarter, versus a consensus estimate of $12 billion. In the same period a year earlier, the company posted earnings per share of $1.46. The company’s revenue for the quarter increased 8.0% on an annual basis.

(A d)

We’ve found a biotech company that has developed a shocking breakthrough medical discovery that could change the way we practice medicine!

And smart investors should beware…

Several research companies have recently weighed in on BMY. TheStreet upgraded Bristol-Myers Squibb shares from a “c+” rating to a “b” rating in a report on Wednesday, November 17. Wells Fargo & Company raised its price target on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company an “equal weight” rating in a research report on Wednesday. BMO Capital Markets began covering Bristol-Myers Squibb in a research report on Thursday, November 18. They set an “outperform” rating and a price target of $72.00 for the company. Finally, the Goldman Sachs group began covering Bristol-Myers Squibb in a research report on Friday, December 17. They set a “buy” rating and a price target of $72.00 for the company. Four equity research analysts gave the stock a hold rating and six gave the company a buy rating. Based on data from MarketBeat.com, the stock has an average buy rating and an average price target of $66.78.

In other Bristol-Myers Squibb news, CEO Giovanni Caforio sold 30,000 shares of the company in a trade dated Thursday, February 24. The stock was sold at an average price of $67.00, for a total transaction of $2,010,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available via this link. Insiders hold 0.11% of the company’s shares.

A number of large investors have recently increased or reduced their holdings in BMY. Dynamic Technology Lab Private Ltd increased its position in Bristol-Myers Squibb shares by 185.2% during the third quarter. Dynamic Technology Lab Private Ltd now owns 24,513 shares in the biopharmaceutical company worth $1,450,000 after buying an additional 15,919 shares in the last quarter. Stonebridge Capital Advisors LLC increased its position in Bristol-Myers Squibb shares by 4.8% during the third quarter. Stonebridge Capital Advisors LLC now owns 144,196 shares of the biopharmaceutical company worth $8,532,000 after buying an additional 6,651 shares last quarter. Forsta AP Fonden increased its position in Bristol-Myers Squibb shares by 23.5% during the third quarter. Forsta AP Fonden now owns 550,700 shares of the biopharmaceutical company worth $32,585,000 after buying an additional 104,800 shares last quarter. Cubist Systematic Strategies LLC increased its position in Bristol-Myers Squibb shares by 215.0% during the third quarter. Cubist Systematic Strategies LLC now owns 197,512 shares of the biopharmaceutical company worth $11,687,000 after purchasing an additional 134,815 shares last quarter. Finally, Brandywine Global Investment Management LLC increased its position in Bristol-Myers Squibb shares by 20.1% during the third quarter. Brandywine Global Investment Management LLC now owns 698,785 shares of the biopharmaceutical company worth $41,347,000 after purchasing an additional 117,132 shares last quarter. Institutional investors hold 72.00% of the company’s shares.

BMY rose $0.25 on Friday, hitting $69.36. The company had a trading volume of 13,076,179 shares, compared to an average volume of 15,367,154. Bristol-Myers Squibb has a 52-week low of $53.22 and a 52-week high of $69.75. The company has a debt ratio of 1.10, a quick ratio of 1.43 and a current ratio of 1.52. The company has a 50-day simple moving average of $65.26 and a 200-day simple moving average of $62.05. The company has a market capitalization of $151.18 billion, a price/earnings ratio of 22.23, a P/E/G ratio of 1.32 and a beta of 0.54.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, May 2. Investors of record on Friday, April 1 will receive a dividend of $0.54. The ex-dividend date is Thursday, March 31. This represents an annualized dividend of $2.16 and a yield of 3.11%. Bristol-Myers Squibb’s payout ratio is 69.23%.

Bristol-Myers Squibb Company Profile (Get a rating)

Bristol Myers Squibb Co engages in the discovery, development, licensing, manufacture, marketing, distribution and sale of biopharmaceuticals. It offers chemically synthesized drugs or small molecules and products derived from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Recommended Stories

Get a Free Copy of Zacks’ Research Report on Bristol-Myers Squibb (BMY)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

Bristol-Myers Squibb (NYSE:BMY) earnings history and estimates

This instant news alert was powered by MarketBeat’s storytelling science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Bristol-Myers Squibb right now?

Before you consider Bristol-Myers Squibb, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Bristol-Myers Squibb didn’t make the list.

While Bristol-Myers Squibb currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

Share.

Comments are closed.